Ready to automate your 3D cell-based assay?
3D Assay Technology
Our proprietary microfluidic technology allows for precise control of fluid movement within the flowchips. The various protocol steps are executed via the touchscreen on the Pu·MA System.
Assay workflows enabled by our technology:
- In situ supernatant sampling
- Sequential drug addition
- In situ lysis for metabolomics
- Immunofluorescence workflow
Organoid Research Award (North America)
At Protein Fluidics we enable researchers to achieve their next breakthrough using automated assays. We support applications such as oncology, T-cell therapy, neuroscience, metabolism and drug-discovery.
Tell us, how would you benefit from an automated workflow for your 3D cell-models?
Apply today for our Organoid Research Award (North America).
Award: A Pu·MA System 3D for your Lab
Submission: Dates: Oct 1 – Dec 1, 2021
View our webinar recording featuring this application
In-depth characterization of a new patient-derived xenograft model for metaplastic breast carcinoma to identify viable biologic targets and patterns of matrix evolution within rare tumor types.
Figure 4C from the publication showing TU-BcX-4IC organoids treated with different paclitaxel concentration and stained with live/dead cytotoxicity and Hoechst nuclear stain using the Pu·MA system. Confocal images of the organoids were acquired within the flowchips.
Protein Fluidics, Inc.
875 Cowan Road, Suite B,
Burlingame, CA 94010
+1 650 529 5080
#pumasystem #flowchip #3dcellassay